Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 5,781 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pediatric Clear all
Completed Not applicable Interventional Results available

Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI).

NCT02820350
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SCD-F40
Device
Lead sponsor
CytoPherx, Inc
Industry
Eligibility
2 Years to 22 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 30, 2026, 3:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774
View directory record Official record
Conditions
Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
Interventions
Tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

NCT04557735
View directory record Official record
Conditions
Thrombotic Microangiopathy
Interventions
Ravulizumab, Best Supportive Care
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
8
States / cities
Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Not applicable Interventional Results available

Computer-Assisted Self-Interviews and Health Screening in the Pediatric Emergency Department

NCT01708317
View directory record Official record
Conditions
Gonorrhea, Chlamydia
Interventions
ACASI
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
15 Years to 21 Years
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 30, 2026, 3:56 PM EDT
Recruiting Phase 1 Interventional

Dexamethasone Use in Pediatric Rhabdomyolysis Patients in Addition to Standard Protocols

NCT06429982
View directory record Official record
Conditions
Rhabdomyolysis
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

NCT03213691
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
Interventions
Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 1 Interventional

Study of MEDI 507 in the Treatment of Pediatric Patients

NCT00813618
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2008 · Synced Oct 30, 2026, 3:56 PM EDT
Recruiting Not applicable Interventional

Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity

NCT06464497
View directory record Official record
Conditions
Obesity, Childhood, Diet, Healthy, Body Weight Changes
Interventions
Whole Foods MyPlate Group
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
10 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Painted Playgrounds Aim 1

NCT03890913
View directory record Official record
Conditions
Childhood Obesity
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 3:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

El Sendero: Pathways to Health Study

NCT05551650
View directory record Official record
Conditions
Obesity, Childhood, Child Development
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
6 Years to 6 Years
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 30, 2026, 3:56 PM EDT
Recruiting No phase listed Observational

Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)

NCT06847282
View directory record Official record
Conditions
Muscular Dystrophy, Facioscapulohumeral
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Palo Alto, California • Iowa City, Iowa • Kansas City, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Completed No phase listed Observational

Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

NCT01873976
View directory record Official record
Conditions
Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
Up to 20 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Intravenous Fluids in Pediatric Migraine

NCT06182098
View directory record Official record
Conditions
Migraine, Migraine in Children
Interventions
1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 3 Interventional

Treatment of Obsessive-Compulsive Disorder (OCD) in Children

NCT00000384
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Cognitive Behavior Therapy, Educational Support, Sertraline
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
8 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 30, 2026, 3:56 PM EDT
Active, not recruiting No phase listed Observational

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

NCT04687358
View directory record Official record
Conditions
Recurrent Pericarditis
Interventions
Not listed
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
7 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04501614
View directory record Official record
Conditions
Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL)
Interventions
Ponatinib, Chemotherapy Agents
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Year to 21 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 4 Interventional Results available

Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries

NCT02132247
View directory record Official record
Conditions
Athletic Injuries
Interventions
Diclofenac hydroxyethylpyrrolidine
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
6 Years to 16 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 30, 2026, 3:56 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Barriers and Facilitators in Access to OT/PT in Pediatric Cancer Survivors

NCT05305950
View directory record Official record
Conditions
Pediatric Cancer
Interventions
Patient population
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 1 Interventional

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

NCT01525004
View directory record Official record
Conditions
Pediatric Solid Organ Transplant Patients
Interventions
High-Dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
3 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

NCT03978143
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 15, 2019 · Synced Oct 30, 2026, 3:56 PM EDT
Completed No phase listed Observational

Measuring the Weight Status, Primary Care Usage and Dietary Intake in the Pediatric Emergency Department

NCT02265185
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
2 Years to 10 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis and Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 30, 2026, 3:56 PM EDT
Not listed Phase 1 Interventional

Oxygen Toxicity of HBOT in Chronic Brain Injury

NCT00592891
View directory record Official record
Conditions
Adult and Pediatric Chronic Cerebral Disorders
Interventions
Hyperbaric oxygen therapy
Drug
Lead sponsor
Paul G. Harch, M.D.
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Marrero, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 30, 2026, 3:56 PM EDT
Completed Phase 1 Interventional

Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

NCT01169584
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Lymphoma, Wilm's Tumor, Ewing's Sarcoma
Interventions
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Drug
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
2 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 3:56 PM EDT
Withdrawn Phase 4 Interventional

Prochlorperazine Versus Prochlorperazine & Ketorolac in Treatment of Pediatric Migraine in the Emergency Department

NCT01534806
View directory record Official record
Conditions
Migraine
Interventions
Ketorolac, Placebo
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 30, 2026, 3:56 PM EDT